Role of P2Y1 purinoceptor in ADP-induced platelet activation
ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induce...
Saved in:
Published in | FEBS letters Vol. 422; no. 3; pp. 291 - 295 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier B.V
06.02.1998
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [
33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [
33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone. |
---|---|
AbstractList | ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [
33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [
33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone. ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone. ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone.ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP-induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [33P]2-MeS-ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [33P]2-MeS-ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti-ADP agent. A3P5PS specifically inhibited 2-MeS-ADP-induced shape change and calcium increase but did not affect adenylyl cyclase down-regulation. 2-MeS-ADP-induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non-aggregating compound, therefore suggesting that P2Y1-mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP-induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone. ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA library confirmed the presence of mRNA of the P2Y1 receptor in platelets. In order to determine if these P2Y1 receptors were involved in ADP‐induced platelet activation, we determined the effects of A3P5PS, an antagonist of the P2Y1 receptor, on the binding of [ 33 P]2‐MeS‐ADP, a potent analogue of ADP. We found that A3P5PS displaced about 27% of [ 33 P]2‐MeS‐ADP binding, a receptor population which has been shown to be resistant to treatment with clopidogrel, a selective anti‐ADP agent. A3P5PS specifically inhibited 2‐MeS‐ADP‐induced shape change and calcium increase but did not affect adenylyl cyclase down‐regulation. 2‐MeS‐ADP‐induced platelet aggregation was also inhibited by A3P5PS but was restored when platelets were further activated by serotonin, a non‐aggregating compound, therefore suggesting that P2Y1‐mediated stimulation is an absolute prerequisite for ADP to induce platelet aggregation and a key event for platelet activation and aggregation to occur. These results therefore show that ADP‐induced aggregation cannot be attributed to activation of P2Y1 alone, but must be attributed to the simultaneous activation of the high affinity receptor (P2Y1) and a low affinity receptor of ADP (still to be discovered), each of them essential, but neither able to trigger aggregation alone. |
Author | Savi, P Beauverger, P Kaghad, M Labouret, C Delfaud, M Salel, V Herbert, J.M |
Author_xml | – sequence: 1 givenname: P surname: Savi fullname: Savi, P – sequence: 2 givenname: P surname: Beauverger fullname: Beauverger, P – sequence: 3 givenname: C surname: Labouret fullname: Labouret, C – sequence: 4 givenname: M surname: Delfaud fullname: Delfaud, M – sequence: 5 givenname: V surname: Salel fullname: Salel, V – sequence: 6 givenname: M surname: Kaghad fullname: Kaghad, M – sequence: 7 givenname: J.M surname: Herbert fullname: Herbert, J.M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/9498802$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkU1L5TAUhsPgoFednyB0JbqokzRtc4KC-O2AoMy4cRXa5BQivU1NUsV_b9t7ceHGWQXyfuScJ9tko3MdErLH6BGjrPz9j1KWp4WQ_EDCIaU0K1L4QRYMBE95XsIGWXxatsh2CM-jiQGTm2RT5hKAZgty8te1mLgmecieWNIP3nZOYx-dT2yXnF0-pLYzg0aT9G0VscWYVDra1ypa1-2Sn03VBvy1PnfI4_XV48Vtend_8-fi7C7VBQdIdQnMcJCF0VlmgJqywIpzwVGwmkohjQZoJOdFKUqd5TWr66IuDWvGPTnwHbK_qu29exkwRLW0QWPbVh26ISghRcZkLkbj3to41Es0qvd2Wfl3td521IuVrr0LwWPz6WBUTVDVDFVNxJQENUNV0wDHX3LaxplA9JVtv03frtJvtsX3_3tSXV-dZ7MyCRLm66nqdFWFI-1Xi14FbbEbv8d61FEZZ78Z5gMJBqIA |
CitedBy_id | crossref_primary_10_1002_wmts_97 crossref_primary_10_1038_sj_bjp_0704673 crossref_primary_10_1080_09537100410001682788 crossref_primary_10_1124_mol_64_5_1210 crossref_primary_10_1046_j_1538_7836_2003_00003_x crossref_primary_10_1074_jbc_274_41_29108 crossref_primary_10_1080_09537100701708498 crossref_primary_10_1007_s40256_019_00345_5 crossref_primary_10_1172_JCI8399 crossref_primary_10_1182_blood_V97_3_587 crossref_primary_10_1080_09537100600757794 crossref_primary_10_1074_jbc_274_40_28293 crossref_primary_10_1016_S0165_1838_00_00136_3 crossref_primary_10_1016_j_atherosclerosis_2008_08_023 crossref_primary_10_1074_jbc_M110714200 crossref_primary_10_1016_S0014_5793_98_01049_7 crossref_primary_10_1182_blood_2005_07_3040 crossref_primary_10_1182_blood_V99_1_193 crossref_primary_10_1038_ki_2008_613 crossref_primary_10_1016_j_jep_2021_114306 crossref_primary_10_1515_BC_2000_051 crossref_primary_10_1007_s00424_011_1010_x crossref_primary_10_1124_mol_117_109660 crossref_primary_10_1046_j_1365_2141_1998_01056_x crossref_primary_10_1074_jbc_M207256200 crossref_primary_10_1172_JCI12242 crossref_primary_10_1517_14656566_6_5_755 crossref_primary_10_1021_jm4013906 crossref_primary_10_1007_s12185_012_1188_5 crossref_primary_10_1038_sj_bjp_0703046 crossref_primary_10_1073_pnas_0510446103 crossref_primary_10_2165_00003495_200060020_00012 crossref_primary_10_1007_s11302_011_9247_6 crossref_primary_10_1177_1536012120927609 crossref_primary_10_3390_brainsci3020540 crossref_primary_10_1016_S0014_2999_98_00985_6 crossref_primary_10_2492_inflammregen_26_446 crossref_primary_10_1006_phrs_2001_0861 crossref_primary_10_1161_01_RES_0000251742_71301_16 crossref_primary_10_1016_j_jmgm_2006_09_006 crossref_primary_10_1097_00001721_200404000_00001 crossref_primary_10_1182_blood_2002_02_0642 crossref_primary_10_1016_S0006_2952_00_00279_3 crossref_primary_10_1038_sj_bjp_0704486 crossref_primary_10_1074_jbc_M407783200 crossref_primary_10_1080_0953710031000092794 crossref_primary_10_1111_j_1365_2141_2010_08499_x crossref_primary_10_1038_13522 crossref_primary_10_1007_s11302_012_9303_x crossref_primary_10_1161_01_ATV_0000057809_32354_22 crossref_primary_10_1016_S0014_5793_99_01313_7 crossref_primary_10_1006_bbrc_1999_9558 crossref_primary_10_1073_pnas_95_14_8070 crossref_primary_10_1182_blood_V99_9_3228 crossref_primary_10_1039_C1AY05530E crossref_primary_10_1002__SICI_1098_2299_199810_45_2_67__AID_DDR3_3_0_CO_2_C crossref_primary_10_1111_j_1538_7836_2004_00556_x crossref_primary_10_1097_00062752_200109000_00002 crossref_primary_10_1182_blood_2005_02_0725 crossref_primary_10_1038_sj_bjp_0702690 crossref_primary_10_1182_blood_V94_12_4156_424k29_4156_4165 crossref_primary_10_1002_rth2_12149 crossref_primary_10_1002__SICI_1098_2299_199811_12_45_3_4_135__AID_DDR8_3_0_CO_2_B crossref_primary_10_1046_j_1365_2141_2003_04166_x crossref_primary_10_1093_eurheartj_sul047 crossref_primary_10_1016_S0026_895X_24_12601_6 crossref_primary_10_1182_blood_V94_12_4156 crossref_primary_10_1002_ddr_1117 crossref_primary_10_1007_s11302_015_9462_7 crossref_primary_10_1152_ajpheart_00110_2002 crossref_primary_10_1007_BF02982079 crossref_primary_10_1146_annurev_pharmtox_46_120604_141207 crossref_primary_10_1002_cmdc_201402141 crossref_primary_10_1016_j_ijbiomac_2016_12_002 crossref_primary_10_1152_physrev_00003_2005 crossref_primary_10_1161_01_ATV_19_10_2281 crossref_primary_10_1016_j_bcmd_2005_12_024 crossref_primary_10_1002_ddr_1108 crossref_primary_10_1007_s40265_013_0126_z crossref_primary_10_1046_j_1538_7836_2003_00266_x crossref_primary_10_1592_phco_26_3_388 crossref_primary_10_1002_ddr_1109 crossref_primary_10_1038_sj_bjp_0703816 crossref_primary_10_1097_00019501_200302000_00008 crossref_primary_10_1182_blood_V96_6_2134 crossref_primary_10_1016_S0014_2999_99_00201_0 crossref_primary_10_1097_00005344_200204000_00008 crossref_primary_10_1016_S0165_6147_98_01271_1 crossref_primary_10_1016_j_pharmthera_2009_10_008 crossref_primary_10_1016_j_pharmthera_2005_03_009 crossref_primary_10_1515_LabMed_2002_064 crossref_primary_10_1007_s12265_012_9445_9 crossref_primary_10_1016_S0165_1838_00_00151_X crossref_primary_10_1124_pr_58_3_3 crossref_primary_10_1161_01_CIR_103_5_718 crossref_primary_10_1046_j_0014_2956_2001_02448_x crossref_primary_10_3390_molecules23020374 crossref_primary_10_1006_bbrc_2001_4816 crossref_primary_10_1016_S0898_6568_00_00083_8 crossref_primary_10_1172_JCI12818 crossref_primary_10_1211_jpp_61_04_0014 crossref_primary_10_1182_blood_V96_10_3439_h8003439_3439_3446 crossref_primary_10_1016_S0014_2999_98_00305_7 crossref_primary_10_1161_01_ATV_19_8_2007 crossref_primary_10_1111_j_1538_7836_2006_02192_x crossref_primary_10_1016_S0049_3848_99_00124_3 crossref_primary_10_1093_abbs_gmr023 crossref_primary_10_1038_84667 crossref_primary_10_1038_sj_bjp_0703517 crossref_primary_10_1182_blood_V96_6_2134_h8002134_2134_2139 crossref_primary_10_1007_s11302_011_9227_x crossref_primary_10_1055_s_0040_1714745 crossref_primary_10_1111_j_1538_7836_2007_02866_x crossref_primary_10_1161_01_CIR_100_15_1667 crossref_primary_10_1182_blood_V96_10_3439 |
Cites_doi | 10.1006/bbrc.1996.0139 10.1046/j.1365-2141.1997.3133126.x 10.1016/S0014-5793(97)00022-7 10.1042/bj2630377 10.1016/0049-3848(82)90061-5 10.1042/bj3120775 10.1016/S0021-9258(19)36687-6 10.1113/jphysiol.1985.sp015850 10.1042/bj2840923 10.1016/S0140-6736(96)09457-3 10.1016/0378-1119(96)00027-3 10.1016/S0021-9258(19)83641-4 10.1136/jcp.19.2.148 10.1016/0014-5793(82)81234-9 10.1182/blood.V52.2.453.453 10.1046/j.1365-2141.1997.d01-2132.x 10.1042/bj1760083 10.1055/s-0038-1650012 10.1006/bbrc.1996.0640 10.1016/0049-3848(94)90186-4 10.1016/0009-8981(80)90378-2 10.1016/S0165-6147(96)01038-3 10.1002/(SICI)1098-1128(199603)16:2<159::AID-MED2>3.0.CO;2-# 10.1111/j.1527-3466.1993.tb00275.x 10.1055/s-0038-1650674 10.1038/194927b0 |
ContentType | Journal Article |
Copyright | 1998 Federation of European Biochemical Societies FEBS Letters 422 (1998) 1873-3468 © 2015 Federation of European Biochemical Societies |
Copyright_xml | – notice: 1998 Federation of European Biochemical Societies – notice: FEBS Letters 422 (1998) 1873-3468 © 2015 Federation of European Biochemical Societies |
DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/S0014-5793(98)00025-8 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry Biology |
EISSN | 1873-3468 |
EndPage | 295 |
ExternalDocumentID | 9498802 10_1016_S0014_5793_98_00025_8 FEB2S0014579398000258 S0014579398000258 |
Genre | article Journal Article |
GroupedDBID | --- --K -~X .55 .~1 0R~ 0SF 1B1 1OC 1~. 1~5 24P 29H 2WC 33P 4.4 4G. 53G 5GY 5RE 5VS 6I. 7-5 71M 8P~ AABNK AACTN AAEDW AAESR AAFTH AAHHS AAIKJ AAJUZ AALRI AANLZ AAQFI AAQXK AASGY AAXRX AAXUO AAZKR ABBQC ABCUV ABEFU ABFNM ABFRF ABGSF ABHUG ABJNI ABLJU ABMAC ABQWH ABVKL ABXDB ABXGK ACAHQ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIUM ACMXC ACNCT ACPOU ACXBN ACXQS ADAWD ADBBV ADBTR ADDAD ADEOM ADEZE ADIYS ADKYN ADMGS ADMUD ADOZA ADQTV ADUVX ADXAS ADZMN ADZOD AEEZP AEFWE AEGXH AEKER AENEX AEQDE AEQOU AEUQT AEUYR AEXQZ AFBPY AFFNX AFFPM AFGKR AFPWT AFVGU AFZJQ AGHFR AGJLS AGYEJ AHBTC AHPSJ AI. AIACR AIAGR AITUG AIURR AIWBW AJBDE AJRQY ALMA_UNASSIGNED_HOLDINGS AMRAJ AMYDB AZFZN AZVAB BAWUL BFHJK BMXJE C45 CBWCG CS3 DCZOG DIK DOVZS DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FUBAC G-Q GBLVA GI5 GX1 HVGLF HZ~ IHE IXB J1W KBYEO L7B LATKE LCYCR LEEKS LITHE LOXES LUTES LX3 LYRES M41 MEWTI MO0 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N9A NCXOZ O-L O9- OK1 OVD OZT P-8 P-9 P2P P2W PC. Q38 R2- R9- RIG RNS ROL RPZ SCC SDF SDG SDP SEL SES SEW SFE SSZ SUPJJ SV3 TEORI TR2 UHB UNMZH VH1 WBKPD WH7 WIH WIJ WIK WIN WOHZO WXSBR X7M XFK Y6R YK3 ZA5 ZGI ZZTAW ~02 AAHBH AAHQN AAIPD AAMNL AAYCA ABWVN ACRPL ADNMO ADVLN AFWVQ AITYG AKRWK ALUQN ALVPJ HGLYW AAYWO AAYXX ACVFH ADCNI AEUPX AEYWJ AFPUW AGQPQ AGYGG AIGII AKBMS AKYEP CITATION CGR CUY CVF ECM EIF NPM PKN 7X8 AAMMB AEFGJ AGXDD AIDQK AIDYY |
ID | FETCH-LOGICAL-c5388-c681d3895dc22d80d65ea3373e71b0979dc88f9335676c24b1bb5b6d1f016383 |
IEDL.DBID | .~1 |
ISSN | 0014-5793 |
IngestDate | Fri Jul 11 03:14:22 EDT 2025 Wed Feb 19 02:33:24 EST 2025 Tue Jul 01 03:51:42 EDT 2025 Thu Apr 24 23:01:21 EDT 2025 Wed Jan 22 16:33:00 EST 2025 Fri Feb 23 02:32:43 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | Adenosine diphosphate Platelet aggregation P2Y1 purinoceptor |
Language | English |
License | http://www.elsevier.com/open-access/userlicense/1.0 http://onlinelibrary.wiley.com/termsAndConditions#vor |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c5388-c681d3895dc22d80d65ea3373e71b0979dc88f9335676c24b1bb5b6d1f016383 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0014579398000258 |
PMID | 9498802 |
PQID | 79721947 |
PQPubID | 23479 |
PageCount | 5 |
ParticipantIDs | proquest_miscellaneous_79721947 pubmed_primary_9498802 crossref_primary_10_1016_S0014_5793_98_00025_8 crossref_citationtrail_10_1016_S0014_5793_98_00025_8 wiley_primary_10_1016_S0014_5793_98_00025_8_FEB2S0014579398000258 elsevier_sciencedirect_doi_10_1016_S0014_5793_98_00025_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | February 06, 1998 |
PublicationDateYYYYMMDD | 1998-02-06 |
PublicationDate_xml | – month: 02 year: 1998 text: February 06, 1998 day: 06 |
PublicationDecade | 1990 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | FEBS letters |
PublicationTitleAlternate | FEBS Lett |
PublicationYear | 1998 |
Publisher | Elsevier B.V |
Publisher_xml | – name: Elsevier B.V |
References | Rink, Smith, Tsien (BIB28) 1982; 148 Savi, Bornia, Salel, Delfaud, Herbert (BIB29) 1997; 98 Léon, Vial, Cazenave, Gachet (BIB16) 1996; 171 Janssens, Communi, Pirotton, Samson, Parmentier, Boeynaems (BIB15) 1996; 221 Peerschke, Zucker (BIB27) 1980; 43 Siess, Lapetina (BIB26) 1989; 263 Born (BIB10) 1962; 194 CAPRIE Steering Committee (1996) Lancet 348, 1329–1339. Meurs, Kauffman, Koeter, Devries (BIB12) 1980; 106 Mills (BIB5) 1996; 76 Savi, Laplace, Maffrand, Herbert (BIB14) 1994; 269 Bachelot, Cano, Grelac, Saleun, Druker, Levy-Toledano, Fischer, Rendu (BIB22) 1992; 284 Hallam, Scrutton, Wallis (BIB25) 1982; 27 Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989) in: Molecular Cloning. A Laboratory Manual, 2nd edn., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. Léon, Hechler, Vial, Leray, Cazenave, Gachet (BIB6) 1997; 403 Ohlmann, Laugwitz, Nurnberg, Spicher, Schultz, Cazenave, Gachet (BIB30) 1995; 312 Colman, R.W. (1987) in: Modern Methods in Pharmacology (Colman, R.W., Ed.), Vol. 4. Methods for Studying Platelets and Megakaryocytes, pp. 33–40, Alan R. Liss, New York. Bouaboula, Legoux, Pessegue, Delpech, Dumont, Piechacyk, Casellas, Shire (BIB9) 1992; 267 Mustard, Packham, Kinlough-Rathbone, Perry, Regoeczi (BIB24) 1978; 52 O'Brien, Heywood (BIB19) 1966; 19 Hallam, Rink (BIB20) 1985; 368 Fredholm, Abbracchio, Burnstock, Dubyak, Harden, Jacobson, Schwabe, Williams (BIB4) 1997; 18 Ayyanathan, Webbs, Sandhu, Athwal, Barnar, Kunapuli (BIB17) 1996; 218 Haslam, Davidson, Desjardins (BIB21) 1978; 176 Savi, Herbert (BIB3) 1996; 16 Savi, Laplace, Herbert (BIB7) 1994; 76 Grynkiewicz, Poenie, Tsien (BIB13) 1985; 260 Herbert, Frehel, Vallée, Kieffer, Gouy, Berger, Necciari, Defreyn, Maffrand (BIB1) 1993; 11 Boyer, Romero-Avila, Schachter, Harden (BIB18) 1996; 50 Savi, Artcanuthurry, Bornia, Grelac, Maclouf, Levy-Toledano, Herbert (BIB23) 1997; 97 1966; 19 1992; 284 1978; 52 1992; 267 1980; 43 1996; 50 1985; 368 1978; 176 1996; 221 1982; 148 1995; 312 1996; 16 1985; 260 1996; 76 1980; 106 1997; 403 1982; 27 1994; 269 1997; 98 1997; 97 1993; 11 1989; 263 1962; 194 1997; 18 1996; 171 1996; 218 1994; 76 Boyer J.L. (e_1_2_4_19_1) 1996; 50 Savi P. (e_1_2_4_15_1) 1994; 269 e_1_2_4_21_1 e_1_2_4_20_1 e_1_2_4_23_1 e_1_2_4_22_1 e_1_2_4_25_1 e_1_2_4_24_1 e_1_2_4_27_1 e_1_2_4_26_1 e_1_2_4_29_1 e_1_2_4_28_1 e_1_2_4_3_1 e_1_2_4_2_1 e_1_2_4_5_1 e_1_2_4_4_1 e_1_2_4_7_1 e_1_2_4_6_1 e_1_2_4_9_1 e_1_2_4_8_1 e_1_2_4_30_1 e_1_2_4_10_1 e_1_2_4_31_1 e_1_2_4_11_1 e_1_2_4_12_1 e_1_2_4_13_1 e_1_2_4_14_1 e_1_2_4_16_1 e_1_2_4_18_1 e_1_2_4_17_1 |
References_xml | – reference: Sambrook, J., Fritsh, E.F. and Maniatis, T. (1989) in: Molecular Cloning. A Laboratory Manual, 2nd edn., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. – volume: 97 start-page: 185 year: 1997 end-page: 191 ident: BIB23 publication-title: Br. J. Haematol. – volume: 11 start-page: 180 year: 1993 end-page: 198 ident: BIB1 publication-title: Cardiovasc. Drug Rev. – reference: CAPRIE Steering Committee (1996) Lancet 348, 1329–1339. – reference: Colman, R.W. (1987) in: Modern Methods in Pharmacology (Colman, R.W., Ed.), Vol. 4. Methods for Studying Platelets and Megakaryocytes, pp. 33–40, Alan R. Liss, New York. – volume: 50 start-page: 1323 year: 1996 end-page: 1329 ident: BIB18 publication-title: Mol. Pharmacol. – volume: 19 start-page: 148 year: 1966 end-page: 153 ident: BIB19 publication-title: J. Clin. Pathol. – volume: 27 start-page: 435 year: 1982 end-page: 445 ident: BIB25 publication-title: Thromb. Res. – volume: 267 start-page: 21830 year: 1992 end-page: 21838 ident: BIB9 publication-title: J. Biol. Chem. – volume: 284 start-page: 923 year: 1992 end-page: 928 ident: BIB22 publication-title: Biochem. J. – volume: 260 start-page: 3440 year: 1985 end-page: 3450 ident: BIB13 publication-title: J. Biol. Chem. – volume: 194 start-page: 927 year: 1962 end-page: 929 ident: BIB10 publication-title: Nature – volume: 312 start-page: 775 year: 1995 end-page: 779 ident: BIB30 publication-title: Biochem. J. – volume: 171 start-page: 295 year: 1996 end-page: 297 ident: BIB16 publication-title: Gene – volume: 98 start-page: 880 year: 1997 end-page: 886 ident: BIB29 publication-title: Br. J. Haematol. – volume: 263 start-page: 377 year: 1989 end-page: 385 ident: BIB26 publication-title: Biochem. J. – volume: 76 start-page: 835 year: 1996 end-page: 856 ident: BIB5 publication-title: Thromb. Haemost. – volume: 269 start-page: 772 year: 1994 end-page: 777 ident: BIB14 publication-title: J. Pharmacol. Exp. Ther. – volume: 52 start-page: 453 year: 1978 end-page: 466 ident: BIB24 publication-title: Blood – volume: 16 start-page: 159 year: 1996 end-page: 179 ident: BIB3 publication-title: Med. Res. Rev. – volume: 106 start-page: 91 year: 1980 end-page: 97 ident: BIB12 publication-title: Clin. Chim. Acta – volume: 148 start-page: 21 year: 1982 end-page: 26 ident: BIB28 publication-title: FEBS Lett. – volume: 403 start-page: 26 year: 1997 end-page: 30 ident: BIB6 publication-title: FEBS Lett. – volume: 18 start-page: 79 year: 1997 end-page: 82 ident: BIB4 publication-title: Trends Pharmacol. Sci. – volume: 218 start-page: 783 year: 1996 end-page: 788 ident: BIB17 publication-title: Biochem. Biophys. Res. Commun. – volume: 43 start-page: 58 year: 1980 end-page: 60 ident: BIB27 publication-title: Thromb. Haemost. – volume: 176 start-page: 83 year: 1978 end-page: 95 ident: BIB21 publication-title: Biochem. J. – volume: 76 start-page: 157 year: 1994 end-page: 169 ident: BIB7 publication-title: Thromb. Res. – volume: 368 start-page: 131 year: 1985 end-page: 146 ident: BIB20 publication-title: J. Physiol. – volume: 221 start-page: 588 year: 1996 end-page: 593 ident: BIB15 publication-title: Biochem. Biophys. Res. Commun. – volume: 148 start-page: 21 year: 1982 end-page: 26 publication-title: FEBS Lett. – volume: 218 start-page: 783 year: 1996 end-page: 788 publication-title: Biochem. Biophys. Res. Commun. – volume: 19 start-page: 148 year: 1966 end-page: 153 publication-title: J. Clin. Pathol. – volume: 260 start-page: 3440 year: 1985 end-page: 3450 publication-title: J. Biol. Chem. – volume: 97 start-page: 185 year: 1997 end-page: 191 publication-title: Br. J. Haematol. – volume: 269 start-page: 772 year: 1994 end-page: 777 publication-title: J. Pharmacol. Exp. Ther. – volume: 312 start-page: 775 year: 1995 end-page: 779 publication-title: Biochem. J. – volume: 76 start-page: 157 year: 1994 end-page: 169 publication-title: Thromb. Res. – volume: 267 start-page: 21830 year: 1992 end-page: 21838 publication-title: J. Biol. Chem. – volume: 106 start-page: 91 year: 1980 end-page: 97 publication-title: Clin. Chim. Acta – volume: 52 start-page: 453 year: 1978 end-page: 466 publication-title: Blood – volume: 76 start-page: 835 year: 1996 end-page: 856 publication-title: Thromb. Haemost. – volume: 284 start-page: 923 year: 1992 end-page: 928 publication-title: Biochem. J. – volume: 263 start-page: 377 year: 1989 end-page: 385 publication-title: Biochem. J. – volume: 11 start-page: 180 year: 1993 end-page: 198 publication-title: Cardiovasc. Drug Rev. – volume: 176 start-page: 83 year: 1978 end-page: 95 publication-title: Biochem. J. – volume: 368 start-page: 131 year: 1985 end-page: 146 publication-title: J. Physiol. – volume: 43 start-page: 58 year: 1980 end-page: 60 publication-title: Thromb. Haemost. – volume: 403 start-page: 26 year: 1997 end-page: 30 publication-title: FEBS Lett. – volume: 194 start-page: 927 year: 1962 end-page: 929 publication-title: Nature – volume: 16 start-page: 159 year: 1996 end-page: 179 publication-title: Med. Res. Rev. – volume: 221 start-page: 588 year: 1996 end-page: 593 publication-title: Biochem. Biophys. Res. Commun. – volume: 50 start-page: 1323 year: 1996 end-page: 1329 publication-title: Mol. Pharmacol. – volume: 98 start-page: 880 year: 1997 end-page: 886 publication-title: Br. J. Haematol. – volume: 171 start-page: 295 year: 1996 end-page: 297 publication-title: Gene – volume: 27 start-page: 435 year: 1982 end-page: 445 publication-title: Thromb. Res. – volume: 18 start-page: 79 year: 1997 end-page: 82 publication-title: Trends Pharmacol. Sci. – ident: e_1_2_4_12_1 – ident: e_1_2_4_18_1 doi: 10.1006/bbrc.1996.0139 – ident: e_1_2_4_30_1 doi: 10.1046/j.1365-2141.1997.3133126.x – ident: e_1_2_4_7_1 doi: 10.1016/S0014-5793(97)00022-7 – ident: e_1_2_4_27_1 doi: 10.1042/bj2630377 – ident: e_1_2_4_26_1 doi: 10.1016/0049-3848(82)90061-5 – ident: e_1_2_4_31_1 doi: 10.1042/bj3120775 – ident: e_1_2_4_10_1 doi: 10.1016/S0021-9258(19)36687-6 – ident: e_1_2_4_21_1 doi: 10.1113/jphysiol.1985.sp015850 – ident: e_1_2_4_23_1 doi: 10.1042/bj2840923 – ident: e_1_2_4_3_1 doi: 10.1016/S0140-6736(96)09457-3 – ident: e_1_2_4_17_1 doi: 10.1016/0378-1119(96)00027-3 – ident: e_1_2_4_14_1 doi: 10.1016/S0021-9258(19)83641-4 – ident: e_1_2_4_20_1 doi: 10.1136/jcp.19.2.148 – ident: e_1_2_4_29_1 doi: 10.1016/0014-5793(82)81234-9 – ident: e_1_2_4_25_1 doi: 10.1182/blood.V52.2.453.453 – volume: 50 start-page: 1323 year: 1996 ident: e_1_2_4_19_1 publication-title: Mol. Pharmacol. – ident: e_1_2_4_24_1 doi: 10.1046/j.1365-2141.1997.d01-2132.x – ident: e_1_2_4_22_1 doi: 10.1042/bj1760083 – ident: e_1_2_4_28_1 doi: 10.1055/s-0038-1650012 – ident: e_1_2_4_16_1 doi: 10.1006/bbrc.1996.0640 – ident: e_1_2_4_8_1 doi: 10.1016/0049-3848(94)90186-4 – ident: e_1_2_4_9_1 – ident: e_1_2_4_13_1 doi: 10.1016/0009-8981(80)90378-2 – ident: e_1_2_4_5_1 doi: 10.1016/S0165-6147(96)01038-3 – ident: e_1_2_4_4_1 doi: 10.1002/(SICI)1098-1128(199603)16:2<159::AID-MED2>3.0.CO;2-# – ident: e_1_2_4_2_1 doi: 10.1111/j.1527-3466.1993.tb00275.x – ident: e_1_2_4_6_1 doi: 10.1055/s-0038-1650674 – volume: 269 start-page: 772 year: 1994 ident: e_1_2_4_15_1 publication-title: J. Pharmacol. Exp. Ther. – ident: e_1_2_4_11_1 doi: 10.1038/194927b0 |
SSID | ssj0001819 |
Score | 1.9896551 |
Snippet | ADP acts as an agonist of platelet aggregation via specific receptors which are still to be characterised. Amplification by PCR of a human platelet cDNA... |
SourceID | proquest pubmed crossref wiley elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 291 |
SubjectTerms | Adenosine diphosphate Adenosine Diphosphate - physiology Animals Calcium - metabolism Clopidogrel Humans In Vitro Techniques P2Y1 purinoceptor Platelet Activation - drug effects Platelet Activation - physiology Platelet aggregation Platelet Aggregation Inhibitors - pharmacology Polymerase Chain Reaction Rabbits Receptors, Purinergic P2 - drug effects Receptors, Purinergic P2 - physiology Receptors, Purinergic P2Y1 Ticlopidine - analogs & derivatives Ticlopidine - pharmacology |
Title | Role of P2Y1 purinoceptor in ADP-induced platelet activation |
URI | https://dx.doi.org/10.1016/S0014-5793(98)00025-8 https://onlinelibrary.wiley.com/doi/abs/10.1016%2FS0014-5793%2898%2900025-8 https://www.ncbi.nlm.nih.gov/pubmed/9498802 https://www.proquest.com/docview/79721947 |
Volume | 422 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEA-lRfRFamvxtNY8iOhD2s3HbhLoy97Zo1qQUiqeT-HysXBw7h61ffDFv91JstujFKn4tht2wjAzO_PLZCZB6C11Vlgf818QDIlwXhDtOSVl4_zcA17QudriS3X6VXyelbMNNBl6YWJZZe_7s09P3rofOeqlebRaLGKPLxUlmJdW8bcuY8OvEDJa-eHvdZkHRLAMgakg8et1F0-eIQ2-1-pDmoSov8Wn-_jzLpxN8Wi6jZ72QBLXmddnaCO0O2i3bmER_eMXfodTaWfKme-gR-Ph6fFkuOBtFx1fdMuAuwafs-8Ur2LavYtFLt0VXrS4_nhOYL0Omvd4tQRECgrGsQsi53Cfo8vpyeXklPSXKRAHPk0RVwEyBYWU3jHmVeGrMsw5lzxIagsttXdKNZrzspKVY8JSa0tbedoUEbLxPbTZdm14gbAElMeq4Atvg2BAVjWwzOBOScd5cHSExCBB4_qDxuN9F0uzrigDwZsoeKOVSYI3aoQOb8lW-aSNhwjUoB5zx2QMRIOHSN8M6jQg9LhHMm9Dd_PTyHiakRZyhPaylm950UKDr2MjVCet_xuPZnoyZvcs9eX_c_4KPcldkYwU1T7avL66Ca8BFl3bg2T3B2irPrv4dgZvn2bjPzqi_nw |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9qReqL1NbS86PNg4g-pN1NstkEfLlee5xaS5ET6lO4fCwcnLtHbR988W93kt3tUYq0-LaEnTDMJDO_TGYyAG9zZ4X1Mf6FzpAK5wXVnue0qJyfecQLus22OJOT7-LzRXGxBqO-FiamVXa2v7XpyVp3I4edNA-X83ms8c1FgctLq7itC_UIHgvcvrGNwcGfVZ4HurAWA-eCxt9XZTztFGnwvVYf0ixU_ctB3QWgt_FsckjjTXjWIUkybJl9Dmuh3oLtYY2n6J-_yTuScjtT0HwLnhz1XxujvsPbNnz81iwCaSpyzn7kZBnj7k3Mcmkuybwmw-Nzigd2VL0nywVCUtQwiWUQbRD3BUzHJ9PRhHbdFKhDqSjqJEJT1EjhHWNeZV4WYcZ5yUOZ20yX2julKs15IUvpmLC5tYWVPq-yiNn4DqzXTR12gZQI85gMPvM2CIZkssJzBneqdJwHlw9A9BI0rntpPDa8WJhVShkK3kTBG61MErxRAzi4IVu2T23cR6B69Zhba8agO7iPdL9Xp0Ghx0uSWR2a61-mjM8ZaVEOYKfV8g0vWmg0dmwAw6T1h_FoxidH7M5Sffn_nO_DxmT69dScfjr78gqetiWSjGbyNaxfXV6HN4iRruxe2gN_AQ0o_vE |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+P2Y1+purinoceptor+in+ADP-induced+platelet+activation&rft.jtitle=FEBS+letters&rft.au=Savi%2C+P&rft.au=Beauverger%2C+P&rft.au=Labouret%2C+C&rft.au=Delfaud%2C+M&rft.date=1998-02-06&rft.pub=Elsevier+B.V&rft.issn=0014-5793&rft.eissn=1873-3468&rft.volume=422&rft.issue=3&rft.spage=291&rft.epage=295&rft_id=info:doi/10.1016%2FS0014-5793%2898%2900025-8&rft.externalDocID=S0014579398000258 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-5793&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-5793&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-5793&client=summon |